dry eye disease

Aldeyra Therapeutics Inc's (NASDAQ: ALDX) Phase 3 TRANQUILITY-2 trial of reproxalap for dry eye disease has achieved the primary endpoint. Reproxalap was statistically superior to the vehicle for each of the two prespecified primary endpoints, Schirmer test and ≥10 mm Schirmer...

Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported topline data from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease. The trial failed to meet the primary endpoint of ocular redness, but it did achieve statistical significance for the dry eye disease...

Ocular Therapeutix Inc (NASDAQ: OCUL) announced topline results from its Phase 2 trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. The clinical trial achieved its pre-specified primary endpoint, demonstrating a...

Aldeyra Therapeutics Inc's (NASDAQ: ALDX) reproxalap achieved the primary endpoint of ocular redness in the Phase 2 trial in patients with dry eye disease. The ocular redness scores in the reproxalap group were statistically lower than those of vehicle. Mean visual analog scale...

The FDA has approved Oyster Point Pharma Inc (NASDAQ: OYST) Tyrvaya (varenicline solution) Nasal Spray 0.03 mg for signs and symptoms of dry eye disease.  Tyrvaya Nasal Spray is the first and only nasal spray approved for dry eye disease.  Related: Oyster Point Inks...

Aerie Pharmaceuticals Inc (NASDAQ: AERI) announced topline results of its Phase 2b COMET-1 study evaluating AR-15512 (TRPM8 Agonist) ophthalmic solution for dry eye disease. The company said that the study failed to achieve statistical significance at pre-determined primary...

Oyster Point Pharma Inc (NASDAQ: OYST) has announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays for dry eye disease in Greater China.  Under the...

Palatin Technologies Inc (NYSE: PTN) has completed an End-of-Phase 2 (EOP2) meeting with the FDA for PL9643 for the treatment of dry eye disease (DED). Palatin remains on track to initiate the Phase 3 program in DED patients during Q4 of 2021, with data readout expected in 2H of...

Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) shares are trading higher after the company received FDA approval to initiate its follow-on pilot study for punctate epitheliopathies (PE). The study will use the Ocular Bandage Gel eye drop to treat patients with PE, which can be associated with dry eyes...

Small-cap biotech Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) fell Tuesday morning following the release of clinical trial results. What Happened Aurinia said a mid-stage study that evaluated its dry eye syndrome treatment Voclosporin ophthalmic solution (VOS) -- 0.2 percent --...

Aldeyra Therapeutics Inc (NASDAQ: ALDX) develops therapies for treating inflammation, inborn errors of metabolism and other diseases related to endogenous aldehyde toxicity. What Happened The clinical-stage biotech announced a Phase 2b clinical trial that evaluated its topical ocular reproxalap in...

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) announced Thursday the release of a 99-cent alternative to Allergan PLC Ordinary Shares (NYSE: AGN)'s Restasis to address the 30 million Americans suffering from Dry Eye Disease. According to Imprimis, Restasis lacks generic competition despite a...